|
Welcome to the Physical Pharmacy & Biopharmaceutics Section |
 |
PPB Section Chair Welcome Letter
Welcome to the PPB Section web page.
As the 2008-2009 PPB Section Chair, I encourage all members of AAPS to use our Section
as a resource, and to consider joining the Section as a Member if your career interests
involve physical pharmacy, biopharmaceutics, and drug delivery. The AAPS PPB Section
is comprised of members from diverse backgrounds in industry, academia, and government
who share a common interest in the field of drug discovery, preformulation, oral
absorption, and drug delivery. The PPB section was formed from the recent AAPS PDD
and PT Section strategic visioning.
The AAPS PPB Section aspires to make AAPS the premier global organization for scientists
involved in physicochemical and biopharmaceutical characterization and delivery
of small molecules and biologics. We provide a dynamic international forum for the
open interchange, discussion and dissemination of emerging scientific developments,
technologies, and regulatory knowledge regarding the principles and practices of
physical pharmacy and biopharmaceutics. We promote the continued growth and development
of the sciences underpinning physicochemical and biopharmaceutic characterization
of small molecules and biologics, pharmaceutical excipients and adjuvants, drug
candidate selection, drug transport and absorption, preformulation, and biopharmaceutic
data guiding the formulation and drug delivery strategies. We foster pharmaceutical
education, career growth, and professional development of the section membership.
Finally, we actively collaborate with and supporting other AAPS sections, focus
groups, and international professional/scientific organizations.
This is your Section; Section leadership exists to coordinate resources so that
we can best meet your needs. The 2008/2009 PPB Section Executive Committee welcomes
your participation and input. Please consider the many ways you can influence our
efforts through active participation as a volunteer. If you would like to discuss
the Section or ways you would like to be involved, contact AAPS or a member of our
Section's executive committee (provided on this Website).
I have been honored to be the chair of this section. I will endeavor to do honor
to serve the PPB section with the finest traditions of the AAPS organization. I
look forward to working with each and every one of you in 2008/2009.
Thanks,
Lawrence X. Yu
2008/2009 PPB Section Chair
Physical Pharmacy and Biopharmaceutics
The Physical Pharmacy and Biopharmaceutics (PPB) Section is composed of AAPS members
whose scientific interests are in the physicochemical and biological factors that
impact the design and delivery of small molecules and biologics. PPB is a multidisciplinary
section that focuses on preformulation, biopharmaceutics, drug absorption, nanotechnology,
and drug delivery systems design and performance including targeted drug delivery.
PPB provides an interactive forum for the exchange of information pertaining to
the selection of developable drug candidates at the drug discovery-development interface,
characterization of drug substance and excipients, studies of relationships between
drugs' physicochemical and biopharmaceutical properties and physiological considerations
at the cellular, organ, and whole animal levels, and overcoming drug absorption
and delivery barriers via drug delivery technologies.
|
|
|
|
|
|
|
|
|
|
Please check back frequently for more information about the brand new PPB Section!
The archived websites for the Pharmaceutics
and Drug Delivery (PDD) Section and the
Pharmaceutical Technologies (PT) Section
are still available for access.
|
|
|
Chair
Michael J. Hageman, Ph.D.
Bristol-Myers Squibb
Princeton, NJ United States
| Chair-Elect
Duxin Sun, Ph.D.
University of Michigan
Ann Arbor, MI UNITED STATES
| Vice Chair
Sherry Ku, Ph.D.
Wyeth Research
Thiells, NY United States
| Secretary/Treasurer
Tycho H. Heimbach, Ph.D.
Novartis Pharmaceuticals Corporation
East Hanover, NJ UNITED STATES
| Past Chair
Lawrence X. Yu, Ph.D.
Food and Drug Administration
North Potomac, MD United States
| Member at Large
Marilyn E. Morris, Ph.D.
University at Buffalo, SUNY
Amherst, NY United States
| National Biotechnology Conference Screeners Committee
Lori S. Burton, Ph.D
Bristol-Myers Squibb, Inc.
New Brunswick, NJ United States
| Annual Meeting Screeners Committee
Nathalie Y. Toussaint, Ph.D.
Bristol-Myers Squibb
Princeton, NJ United States
| Annual Meeting Screeners Committee
Allen C. Templeton, Ph.D
Merck and Co., Inc.
West Point, PA United States
| Annual Meeting Program Committee
Duxin Sun, Ph.D.
University of Michigan
Ann Arbor, MI UNITED STATES
| Awards Committee
Lillian Zhang, Ph.D
CDER, FDA
Silver Spring, MD United States
| Content Advisory Cmte
Ping Tong
Abbott Labs
Abbott Park, IL United States
| National Biotech Progrming Committee
Giovanni M. Pauletti, Ph.D.
University of Cincinnati
Cincinnati, OH United States
| Fellows Committee
Gregory E. Amidon, Ph.D.
University of Michigan
Ann Arbor, MI United States
| Nominations Committee
Michael J. Hageman, Ph.D.
Bristol-Myers Squibb
Princeton, NJ United States
| Program Coordination Committee
Duxin Sun, Ph.D.
University of Michigan
Ann Arbor, MI UNITED STATES
| Communications Committee
Balvinder S. Vig, Ph.D
Bristol Myers Squibb
New Brunswick, NJ UNITED STATES
| Webmasters Committee
Weiyi Li
Anchen Pharmaceuticals
Irvine, CA United States
| Member Strategic Oversight Committee
Phenil J. Patel, Ph.D.
Eli Lilly and Co.
Indianapolis, IN United States
| Communications Committee
Olafur S. Gudmundsson, Ph.D.
Bristol-Myers Squibb Company
Princeton, NJ UNITED STATES
| Staff Liaison
Maria Nadeau
AAPS
Arlington, VA United States
| Staff Liaison
Jake P. Harris
AAPS
Arlington, VA United States
| Dermatopharmaceutics Focus Group
Mr. Steven A. Giannos
Chrono Therapeutics, Inc.
Quincy, MA UNITED STATES
| Excipients Focus Group
Dr. Thomas P. Farrell
Colorcon
West Point, PA UNITED STATES
| Computational Drug Design Focus Group
Herschel J. R. Weintraub
CADDinformatics, Inc.
Sun City, AZ United States
| Inhalation & Nasal Technology Focus Group
Michael T. Riebe, Ph.D.
Merck & Co., Inc.
Collegeville, PA United States
| Intellectual Property Focus Group
Jeffrey A. Lindeman, Ph.D.
O'BRIEN JONES PLLC
McLean, VA
| Lipid-Based Drug Delivery Systems Focus Group
Paul M. Bummer, Ph.D.
University of Kentucky
Lexington, KY UNITED STATES
| Microdialysis Focus Group
Thomas Cremers
Brains On-line
South San Francisco, CA NETHERLANDS
| Modified Release Focus Group
John R. Crison, Ph.D.
Private Consulting
Carlsbad, CA United States
| Nanotechnology Focus Group
Panayiotis P. Constantinides, Ph.D.
Biopharmaceutical and Drug Delivery Consulting, LLC
Gurnee, IL UNITED STATES
| Oral Absorption Focus Group
Lillian Zhang, Ph.D
CDER, FDA
Silver Spring, MD United States
| Preformulation Focus Group
Tapan K. Das, Ph.D.
Pfizer
Chesterfield, MO United States
| Targeted Drug Delivery and Prodrug Focus Group
Victor R Guarino
Bristol-Myers Squibb
Princeton, NJ UNITED STATES
|
|